FDA IND clearance enables a phase 3 program evaluating TRIESENCE for postoperative ocular inflammation and pain following cataract surgery, aiming to broaden on-label use beyond current intraocular ...
Investor's Business Daily on MSN
Why IBD stock of the day Harrow has its sights on a breakout
Harrow is Monday's IBD Stock Of The Day. The biotech stock is setting up to tack a handle onto a seven-week cup.
Harrow (NASDAQ:HROW) executives used the company’s fourth-quarter 2025 earnings call to highlight what CEO Mark Baum ...
The planned Phase 3 study is a randomized, placebo-controlled, double-masked, multicenter clinical trial designed to evaluate the safety and efficacy of TRIESENCE in patients undergoing cataract ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Harrow moved its headquarters to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results